MIR454 (MicroRNA 454)

Drug sensitivity analysis showed that the risk score was significantly correlated with the sensitivity to various chemotherapeutic drugs (e.g., Methotrexate, Paclitaxel). This study established a reliable prognostic risk scoring model for HCC by screening differentially expressed glycolysis-related miRNAs, which effectively distinguishes between high-risk and low-risk patients and predicts patient survival. Additionally, the model is closely associated with the immune microenvironment and drug sensitivity, offering strong support for personalized treatment and clinical decision-making in HCC.

Moreover, the transcription unit presents as a prominent prognostic meta-marker for lung cancer. Collectively, these findings demonstrate the essential and coordinated roles of PRR11-SKA2-miR301a/454 bidirectional transcription unit in lung cancer progression, highlighting its potential diagnostic and therapeutic values in cancers.

miR-454-3p has diagnostic value in BC, and its expression is significantly correlated with tumor deterioration. Combining miR-454-3p and CDUS can improve diagnostic accuracy, providing a reference for early clinical diagnosis of BC.

This study identifies miRNAs and their target genes as critical regulators of inflammation in COPD, MS, and lung cancer. Single-cell insights and pathway enrichment provide a comprehensive view of shared molecular mechanisms, contributing to biomarker discovery and therapeutic strategies for precision medicine in inflammatory diseases.

A single week of LCD induces swift, pathway-linked shifts in plasma exosomal miRNAs in T2D. miR-494-3p and miR-362-5p emerge as promising early biomarkers for long-term glycaemic improvement and weight reduction, respectively.

Moreover, EIF4A3 has binding sites in the upstream region of the GNAI2 pre-mRNA, and we confirmed that circGNAI2 was downregulated by EIF4A3 in TNBC cells. Overall, our study indicates that EIF4A3-regulated circGNAI2 suppresses TNBC progression possibly by regulating the miR-454-3p/VGLL4/STAT3 pathway, providing pivotal potential therapeutic targets for the treatment of TNBC.

Furthermore, a nomogram integrating the miRNA-based model with Milan criteria (MC) was developed and exhibited a high predictive accuracy (AUC =0.926, P<0.001) and clinical applicability, which was remarkably better than that of MC (AUC =0.629, P<0.001). This model may contribute to the reasonable selection of LT candidates in HCC patients and the personalized postoperative management.

Taken together, the results of our study suggest MED12 as a potential target for future PCa treatment in conjunction with enzalutamide resistance. Furthermore, miR-454-3p, which directly targets AR and AR-V7 and indirectly influences c-Myc protein expression, reveals new molecular mechanisms in PCa biology.

P=N/A, N=30, Recruiting, Università Vita-Salute San Raffaele | Not yet recruiting --> Recruiting | Trial primary completion date: May 2026 --> Jan 2027

Exosomal miR-454-3p enhanced the progression of NSCLC cells through HHEX. miR-454-3p may be a therapeutic target for NSCLC.

The low expression of miR-454-3p, miR-7974, and miR-3615 in CRC cells or high expression of miR-130b-3p and miR-4326 in isolated exosomes could predict the response to oxaliplatin therapy. This indicates the potential of these specific miRNAs to serve as predictive markers for the response to oxaliplatin therapy.

P=N/A, N=30, Not yet recruiting, Università Vita-Salute San Raffaele | Initiation date: Sep 2024 --> Jan 2025